Major Ingredients

Each film coated tablet contains Ofloxacin BP 400 mg

Major Functionality

The following infections caused by Ofloxacin susceptible Staphylococcus, Streptococcus pyogenes, Hemolytic streptococci, Streptococcus pneumoniae, Peptostreptococcus sp., Neisseria gonorrhoeae, Escherichia coli, Citrobacter sp., Shigella sp., Klebsiella pneumoniae, Enterobacter sp., Serratia sp., Proteus sp., Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter sp., and Campylobacter sp., a) Pneumonia, Chronic Bronchitis, Diffuse panbronchiolitis, Bronchiectasis with infection, Secondary infections of chronic respiratory diseases. b) Pharyngolaryngitis, Tonsillitis and Acute bronchitis. c) Pyelonephritis, Cystitis, Prostatitis, Epididymitis, Gonococcal urethritis, Nongonococcal urethritis. d) Intrauterine infection, Adnexitis, Bartholinitis. e) Folliculitis, Furuncle, Furunculosis, Carbuncle, Erysipelas phlegmon, Lymphangitis, Felon, Subcutaneous abscess, Spiradenitis, Acne conglobata, Infectious atheroma, Perianal abscess. f) Mastadenitis, Superficial secondary infections after traumas, Burns, Surgery, Traumas. g) Cholecystitis, Cholangitis. h) Otitis media, Sinusitis. i) Blepharitis, Hordeolum, Dacryocystitis, Tarsadenitis, Keratohelcosis. j) Bacillary dysentery, Enteritis. k) Periodontitis, Pericoronitis, Gnathitis. l) Skin & soft tissue infections.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.